In contrast, RALB was associated with an increased risk of ER-negative [OR: 1.40, 95% CI: 1.20 to 1.64; PP4: 0.93] and HER2 enriched tumours [OR: 1.59, 95% CI: 1.14 to 2.25; PP4: 0.98], as well as breast cancer overall [OR: 1.16, 95% CI: 1.09 to 1.23; PP4: 0.70]. Here, RALB is linked to breast cancer.